Yunxiao Meng
Overview
Explore the profile of Yunxiao Meng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
621
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou S, Zhang Y, Belmar J, Hou C, Zhang Y, Peng C, et al.
Cancer Res
. 2025 Feb;
PMID: 39937190
Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial in regulating cell cycle progression and cancer development. Targeting CDK4/6 has shown considerable promise in treating various cancers, including breast cancer. Despite...
2.
Zhang Y, Wei H, Zhou Y, Li Z, Gou W, Meng Y, et al.
Clin Transl Med
. 2021 Dec;
11(12):e649.
PMID: 34954894
No abstract available.
3.
Zhang Y, Wu X, Kai Y, Lee C, Cheng F, Li Y, et al.
JCI Insight
. 2019 Dec;
4(24).
PMID: 31852841
Clinical and preclinical studies show tissue-specific differences in tumorigenesis. Tissue specificity is controlled by differential gene expression. We prioritized genes that encode secreted proteins according to their preferential expression in...
4.
Zhang Y, Li Z, Hao Q, Tan W, Sun J, Li J, et al.
Cancer Res
. 2019 Aug;
79(19):4896-4910.
PMID: 31431461
DNA rereplication leads to genomic instability and has been implicated in the pathology of a variety of human cancers. Eukaryotic DNA replication is tightly controlled to ensure it occurs only...
5.
Li Z, Zhou W, Zhang Y, Sun W, Yung M, Sun J, et al.
Clin Cancer Res
. 2019 Jul;
25(19):5947-5960.
PMID: 31285371
Purpose: Up to 80% of patients with ovarian cancer develop platinum resistance over time to platinum-based chemotherapy. Increased HIF1α level is an important mechanism governing platinum resistance in platinum-resistant ovarian...
6.
Bi Y, Meng Y, Niu Y, Li S, Liu H, He J, et al.
Oncol Rep
. 2019 Mar;
41(5):2762-2774.
PMID: 30816514
The aim of the present study was to examine the whole‑genome DNA methylation status of thymomas and identify differences in thymoma DNA methylation profiles. DNA methylation profiles of tissues (n=12)...
7.
Bi Y, Ren X, Bai X, Meng Y, Luo Y, Cao J, et al.
Eur J Surg Oncol
. 2018 Dec;
45(3):353-358.
PMID: 30528043
Introduction: Few studies have focused on PD-L1 expression in medullary thyroid carcinoma (MTC). Expressions of PD-1 and PD-L1 and their clinicopathologic and prognostic relevance were therefore further investigated on a...
8.
Chen C, Li Y, Hu S, Zhou W, Meng Y, Li Z, et al.
Oncogene
. 2018 Dec;
38(13):2364-2379.
PMID: 30518875
DNA replication machinery is responsible for accurate and efficient duplication of the chromosome. Since inhibition of DNA replication can lead to replication fork stalling, resulting in DNA damage and apoptotic...
9.
Meng Y, Chen C, Yung M, Sun W, Sun J, Li Z, et al.
Cancer Lett
. 2018 Apr;
428:104-116.
PMID: 29704517
The acquisition of resistance is a major obstacle to the clinical use of platinum drugs for ovarian cancer treatment. Increase of DNA damage response is one of major mechanisms contributing...
10.
Zhou W, Sun W, Yung M, Dai S, Cai Y, Chen C, et al.
Oncogene
. 2018 Apr;
37(29):3981-3997.
PMID: 29662190
Antineoplastic platinum agents are used in first-line treatment of ovarian cancer, but treatment failure frequently results from platinum drug resistance. Emerging observations suggest a role of reactive oxygen species (ROS)...